Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK.

J Clin Oncol. 2006 Oct 20;24(30):4914-21.

PMID:
17050875
2.

Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.

Tahara M, Shirao K, Boku N, Yamaguchi K, Komatsu Y, Inaba Y, Arai T, Mizunuma N, Satoh T, Takiuchi H, Nishina T, Sakata Y.

Jpn J Clin Oncol. 2008 Nov;38(11):762-9. doi: 10.1093/jjco/hyn102. Epub 2008 Oct 4.

PMID:
18836202
3.

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA 3rd.

J Clin Oncol. 2008 May 10;26(14):2311-9. doi: 10.1200/JCO.2007.13.1193. Epub 2008 Apr 7.

PMID:
18390971
4.

A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities.

Gamucci T, Nelli F, Cianci G, Grassi G, Moscetti L, Sperduti I, Zeuli M, Cortesi E, D'Auria G, Pollera CF.

Clin Colorectal Cancer. 2008 Jul;7(4):273-9. doi: 10.3816/CCC.2008.n.035.

PMID:
18650196
5.

The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.

Lin JK, Lin AJ, Lin CC, Lan YT, Yang SH, Li AF, Chang SC.

J Surg Oncol. 2011 Nov 1;104(6):661-6. doi: 10.1002/jso.21993. Epub 2011 Jun 13.

PMID:
21671463
6.

Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.

Han HS, Chang HJ, Hong YS, Kim SY, Lee KS, Jung KH.

Dis Colon Rectum. 2009 Jun;52(6):1144-51; discussion 1152-3. doi: 10.1007/DCR.0b013e31819edbf9.

PMID:
19581859
7.

Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.

Bouchahda M, Macarulla T, Spano JP, Bachet JB, Lledo G, Andre T, Landi B, Tabernero J, Karaboué A, Domont J, Levi F, Rougier P.

Crit Rev Oncol Hematol. 2008 Sep;67(3):255-62. doi: 10.1016/j.critrevonc.2008.02.003. Epub 2008 Apr 8.

PMID:
18400508
8.

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E.

N Engl J Med. 2004 Jul 22;351(4):337-45.

9.

Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.

Gebbia V, Del Prete S, Borsellino N, Ferraù F, Tralongo P, Verderame F, Leonardi V, Capasso E, Maiello E, Bordonaro R, Stinco S, Agostara B, Barone C.

Clin Colorectal Cancer. 2006 Mar;5(6):422-8.

PMID:
16635281
10.

Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.

Lévi F, Karaboué A, Gorden L, Innominato PF, Saffroy R, Giacchetti S, Hauteville D, Guettier C, Adam R, Bouchahda M.

Cancer Chemother Pharmacol. 2011 Feb;67(2):339-48. doi: 10.1007/s00280-010-1327-8. Epub 2010 Apr 17.

PMID:
20401611
11.

Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.

Souglakos J, Kalykaki A, Vamvakas L, Androulakis N, Kalbakis K, Agelaki S, Vardakis N, Tzardi M, Kotsakis AP, Gioulbasanis J, Tsetis D, Sfakiotaki G, Chatzidaki D, Mavroudis D, Georgoulias V.

Ann Oncol. 2007 Feb;18(2):305-10. Epub 2006 Nov 1.

PMID:
17079693
12.

Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial.

Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel B, Trodella L, Tonini G.

Br J Cancer. 2006 Mar 27;94(6):792-7.

13.

Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.

Vokes EE, Chu E.

Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):15-25. Review.

PMID:
16736979
14.

Integration of novel agents in the treatment of colorectal cancer.

Iqbal S, Lenz HJ.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. Review.

PMID:
15309512
15.

A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer.

Muro K, Yoshino T, Doi T, Shirao K, Takiuchi H, Hamamoto Y, Watanabe H, Yang BB, Asahi D.

Jpn J Clin Oncol. 2009 May;39(5):321-6. doi: 10.1093/jjco/hyp016. Epub 2009 Mar 14.

PMID:
19287023
16.

A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining.

Wierzbicki R, Jonker DJ, Moore MJ, Berry SR, Loehrer PJ, Youssoufian H, Rowinsky EK.

Invest New Drugs. 2011 Feb;29(1):167-74. doi: 10.1007/s10637-009-9341-6. Epub 2009 Oct 15.

PMID:
19830388
17.

Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.

Zhang W, Gordon M, Lenz HJ.

Ann Med. 2006;38(8):545-51. Review.

PMID:
17438669
18.

Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.

Jean GW, Shah SR.

Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742. Review.

PMID:
18503402
19.

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

Harding J, Burtness B.

Drugs Today (Barc). 2005 Feb;41(2):107-27. Review.

PMID:
15821783
20.

Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study.

Lim R, Sun Y, Im SA, Hsieh RK, Yau TK, Bonaventura A, Cheirsilpa A, Esser R, Mueser M, Advani S.

World J Gastroenterol. 2011 Apr 14;17(14):1879-88. doi: 10.3748/wjg.v17.i14.1879.

Supplemental Content

Support Center